Tetraphase Pharmaceuticals, Inc.
TTPH
TTPH was delisted on the 28th of July, 2020.
92 hedge funds and large institutions have $63.4M invested in Tetraphase Pharmaceuticals, Inc. in 2018 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 31 increasing their positions, 20 reducing their positions, and 13 closing their positions.
55% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 20
16% more call options, than puts
Call options by funds: $1.72M | Put options by funds: $1.48M
15% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 13
2% more funds holding
Funds holding: 90 → 92 (+2)
18% less capital invested
Capital invested by funds: $77.5M → $63.4M (-$14.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$1.63M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.25M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$1.07M |
| 4 |
RA
Royce & Associates
New York
|
+$1.03M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$3.34M |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$2.32M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$1.53M |
| 4 |
HSBC Holdings
London,
United Kingdom
|
-$664K |
| 5 |
Charles Schwab
San Francisco,
California
|
-$509K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PHK
101
Point72 Hong Kong
Hong Kong
| – | -$12K | -175 | Closed |
|
|
CF
102
Centaurus Financial
Anaheim,
California
| – | -$7K | -100 | Closed |
|
103
Parallax Volatility Advisers
San Francisco,
California
| – | -$6K | -80 | Closed |
|
|
PIA
104
Piedmont Investment Advisors
Durham,
North Carolina
| – | -$3K | -45 | Closed |
|
TTPH Hedge Fund Activity: Q3 2018 in Review
92 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Tetraphase Pharmaceuticals, Inc. (TTPH) for Q3 2018, worth a combined $63.4M — down 18% from $77.5M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new TTPH positions and 13 closed out — a net gain of 2 holders — while 31 added to existing stakes and 20 trimmed.
The largest buyer was Two Sigma Investments, opening a new position worth an estimated $1.63M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $3.34M sold.
- 92 institutional investors held Tetraphase Pharmaceuticals, Inc. (TTPH) as of Q3 2018, up from 90 in Q2 2018.
- Funds reported $63.4M of Tetraphase Pharmaceuticals, Inc. stock for Q3 2018, down 18% quarter-over-quarter.
- 15 funds opened new Tetraphase Pharmaceuticals, Inc. positions in Q3 2018 and 13 closed out, a net change of +2 holders.
- The largest Tetraphase Pharmaceuticals, Inc. buyer in Q3 2018 was Two Sigma Investments, an estimated $1.63M added.
- The largest Tetraphase Pharmaceuticals, Inc. seller in Q3 2018 was Baker Bros. Advisors, an estimated $3.34M sold.
Based on aggregated 13F filings for Q3 2018.